Meeting
2013 ASCO Annual Meeting
The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada.
Authors
Sherry Athena Doroja Ruste
Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
Sherry Athena Doroja Ruste , Andrea Eisen , Kathleen I. Pritchard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention/Epidemiology
Track
Cancer Prevention/Epidemiology
Sub Track
Cancer Genetics
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1550)
DOI
10.1200/jco.2013.31.15_suppl.1550
Abstract #
1550
Poster Bd #
3C
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
A multi-institution study of the accuracy of BRCAPRO in predicting BRCA1/BRCA2 mutations in women with ovarian cancer.
First Author: Molly S Daniels
First Author: Emmanouil S. Saloustros
Poster
2023 ASCO Annual Meeting
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Charles Drescher
Poster
2018 ASCO Annual Meeting
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.
First Author: Kirsten Timms